PMID- 32392807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 7
TI  - Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-alpha 
      Inhibitors.
LID - 10.3390/jcm9051377 [doi]
LID - 1377
AB  - This study was performed to evaluate the effects of 15-month anti-tumor necrosis 
      factor alpha (anti-TNF-alpha) therapy on the aggrecan turnover of female rheumatoid 
      arthritis (RA) patients. Serum was obtained from healthy subjects and female RA 
      patients treated with TNF-alpha inhibitors (TNFalphaI) in combination with methotrexate. 
      We measured serum levels of aggrecan chondroitin sulfate 846 epitope (CS846), 
      aggrecan fragments (AGC), disintegrin and metalloproteinase with thrombospondin 
      motifs-4 (ADAMTS-4) and 5 (ADAMTS-5), as well as their natural inhibitor, known 
      as tissue inhibitor of matrix metalloproteinase-3 (TIMP-3), using immunoassay 
      methods. Serum levels of CS846, AGC, ADAMTS-4, ADAMTS-5 and TIMP-3 were higher in 
      female patients with RA before the treatment in comparison to healthy subjects. 
      Ratio of ADAMTS-5 to TIMP-3 was significantly higher in RA women than in 
      controls, whereas ADAMTS-4/TIMP-3 ratio did not differ from that in controls. 
      During the anti-TNF-alpha therapy, the serum levels of 846 epitope increased, whereas 
      levels of AGC decreased in female RA patients. Furthermore, 15 months of 
      treatment with TNFalphaI downregulated serum levels of both ADAMTS, without any 
      effect on TIMP-3 levels. These changes were accompanied by significantly reduced 
      ratios of ADAMTS to TIMP-3. According to our results, anti-TNF-alpha therapy has a 
      beneficial impact on aggrecan remodeling during RA.
FAU - Szeremeta, Anna
AU  - Szeremeta A
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      41-200 Sosnowiec, Poland.
FAU - Jura-Poltorak, Agnieszka
AU  - Jura-Poltorak A
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      41-200 Sosnowiec, Poland.
FAU - Zon-Giebel, Aleksandra
AU  - Zon-Giebel A
AD  - Silesian Center of Rheumatology, Rehabilitation and Prevention of Disability of 
      Gen. Jerzy Zietek in Ustron, 43-450 Ustron, Poland.
FAU - Kopec-Medrek, Magdalena
AU  - Kopec-Medrek M
AD  - Department of Internal Medicine and Rheumatology, Faculty of Medical Sciences in 
      Katowice, Medical University of Silesia, Katowice, 40-635 Katowice, Poland.
FAU - Kucharz, Eugeniusz Jozef
AU  - Kucharz EJ
AD  - Department of Internal Medicine and Rheumatology, Faculty of Medical Sciences in 
      Katowice, Medical University of Silesia, Katowice, 40-635 Katowice, Poland.
FAU - Olczyk, Krystyna
AU  - Olczyk K
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      41-200 Sosnowiec, Poland.
LA  - eng
GR  - 2013/09/N/NZ5/00815/National Science Centre, Poland/
GR  - KNW-2-O21/N/8/N/Medical University of Silesia, Katowice, Poland/
PT  - Journal Article
DEP - 20200507
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7290997
OTO - NOTNLM
OT  - ADAMTS
OT  - AGC
OT  - CS846
OT  - TIMP-3
OT  - aggrecan
OT  - rheumatoid arthritis
OT  - tumor necrosis factor-alpha inhibitors
COIS- The authors declare that there are no conflicts of interest. The funders had no 
      role in the design of the study; in the collection, analyses, or interpretation 
      of data; in the writing of the manuscript, or in the decision to publish the 
      results.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
PMCR- 2020/05/07
CRDT- 2020/05/13 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
PHST- 2020/05/07 00:00 [pmc-release]
AID - jcm9051377 [pii]
AID - jcm-09-01377 [pii]
AID - 10.3390/jcm9051377 [doi]
PST - epublish
SO  - J Clin Med. 2020 May 7;9(5):1377. doi: 10.3390/jcm9051377.